GlaxoSmithKline has licensed non-exclusive rights to Response Genetics' PCR technology and "diagnostic expertise" to assess BRAF gene mutations in human tumor samples. The drug company intends to apply the technology to develop companion diagnostics for BRAF and MEK inhibitors currently under development.

GSK's drug development pipeline, updated as of February, indicates the company has a BRAF protein kinase inhibitor and a MEK inhibitor. Both are in Phase II trials and are being developed as treatments for cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.